Role of Cell-Free DNA in Relapsed Head and Neck Cancer

Abstract

Introduction Owing to the aggressive biology of head and neck squamous cell carcinoma (HNSCC), new biomarkers that can facilitate the diagnosis and tracking of tumour growth are the need of the hour. Liquid biopsy has emerged as an easier tool than tissue biopsy to monitor the emergence of treatment resistance or the recurrence of disease at the molecular level.

Objectives To assess the role of cell-free DNA (cfDNA) as a biomarker for relapsed HNSCC.

Materials and Methods This study is a Phase 2 interventional study (NCT: CTRI/2020/02/023378) that assessed the response rates of a new triplet drug regimen in refractory or relapsed HNSCC. Thirty-five patients underwent blood sampling before the commencement of therapy and at 3 months of treatment. Isolation of cfDNA was done using magnetic beads (molecular weight near 170 kb) for quantification.

Results Twenty-eight patients had comparable data at baseline and after 3 months of treatment. The mean cfDNA reading at baseline was 8.9 ng/μL (range: 2.6 -7.3 ng/μL) of blood. The cfDNA concordance with clinical and radiological outcomes was 54.2%. The patients who responded to therapy were compared over time with patients who did not respond. Repeated measures testing found a significant difference (p 1?4 0.0035) in changes to the cfDNA levels of these two groups.

Conclusion This study posits the potential value of liquid biopsy in the treatment of recurrent HNSCC. Our findings prove the clinical relevance as well as limitations of cfDNA, which warrant extrapolation in an upfront setting too.

Keywords

molecular biomarker - recurrence risk - resistance - cell-free DNA - head and neck tumors - liquid biopsy - mutations

Patient Consent

Patient consent was obtained for this study.

Publikationsverlauf

Artikel online veröffentlicht:
13. Dezember 2024

• References

• 1 Patil VM, Noronha V, Joshi A. et al. A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck. Oral Oncol 2015; 51 (03) 279-286
• 2 Sung H, Ferlay J, Siegel RL. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
• 3 Singhal A, Hussain A, Agarwal A, Thakur B. Current status of cell-free DNA in head and neck cancer management. Annals of Indian Academy of Otorhinolaryngology Head and Neck Surgery 3 (01) 1-7
• 4 Kong L, Birkeland AC. Liquid biopsies in head and neck cancer: current state and future challenges. Cancers (Basel) 2021; 13 (08) 1-16
• 5 Wan JCM, Massie C, Garcia-Corbacho J. et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer 2017; 17 (04) 223-238
• 6 Schwarzenbach H, Hoon DSB, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011; 11 (06) 426-437
• 7 Tokuhisa Y, Iizuka N, Sakaida I. et al. Circulating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinoma. Br J Cancer 2007; 97 (10) 1399-1403
• 8 Palmirotta R, Lovero D, Cafforio P. et al. Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology. Ther Adv Med Oncol 2018; 10: 1758835918794630
• 9 Brandt A, Thiele B, Schultheiß C, Daetwyler E, Binder M. Circulating tumor DNA in head and neck squamous cell carcinoma. Cancers (Basel) 2023; 15 (07) 15
• 10 Baa AK, Sharma A, Bhaskar S. et al. A single-arm feasibility phase II study of EMF (erlotinib + methotrexate + 5-fluorouracil) regimen in platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Ecancermedicalscience 2022; 16: 1451
• 11 Baa AK, Sharma A, Bhaskar S. et al. Role of circulating tumour cells (CTCs) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Ecancermedicalscience 2023; 17: 1578
• 12 Surani A., Poterlowicz K.. (2016) “Circulating tumour DNA: a minimally invasive biomarker for tumour detection and stratification”, British Journal of Pharmacy. 1 (01) 3-18
• 13 Lin LH, Chang KW, Kao SY, Cheng HW, Liu CJ. Increased plasma circulating cell-free DNA could be a potential marker for oral cancer. Int J Mol Sci 2018; 19 (11) 19
• 14 Verma T, Kumari S, Mishra S. et al. Circulating free DNA as a marker of response to chemoradiation in locally advanced head and neck squamous cell carcinoma. Indian J Pathol Microbiol 2020; 63 (04) 521-526
• 15 Koukourakis MI, Xanthopoulou E, Koukourakis IM. et al. Circulating plasma cell-free DNA (cfDNA) as a predictive biomarker for radiotherapy: results from a prospective trial in head and neck cancer. Cancer Diagn Progn 2023; 3 (05) 551-557
• 16 Mazurek AM, Rutkowski T, Fiszer-Kierzkowska A, Małusecka E, Składowski K. Assessment of the total cfDNA and HPV16/18 detection in plasma samples of head and neck squamous cell carcinoma patients. Oral Oncol 2016; 54: 36-41
• 17 Basnet S, Zhang ZY, Liao WQ, Li SH, Li PS, Ge HY. The prognostic value of circulating cell-free DNA in colorectal cancer: a meta-analysis. J Cancer 2016; 7 (09) 1105-1113
• 18 Hovhannisyan G, Harutyunyan T, Aroutiounian R, Liehr T. The diagnostic, prognostic, and therapeutic potential of cell-free DNA with a special focus on COVID-19 and other viral infections. Int J Mol Sci 2023; 24 (18) 24